Results 41 to 50 of about 40,229 (203)

A case series of necrotizing periodontal diseases in hospitalized patients: What hasn't been said yet?

open access: yesClinical Advances in Periodontics, EarlyView.
Abstract Background Necrotizing periodontal diseases (NPDs) are uncommon and severe inflammatory conditions characterized by tissue necrosis, painful ulceration, and rapid clinical progression, frequently associated with systemic immunosuppression. Limited data exist regarding their clinical presentation and management in hospital settings.
Osmaria Letthycia Carvalho Leal   +8 more
wiley   +1 more source

Cefepime-Resistant Pseudomonas aeruginosa

open access: yes, 2011
Resistance to extended-spectrum cephalosporins complicates treatment of Pseudomonas aeruginosa infections. To elucidate risk factors for cefepime-resistant P.
Ebbing Lautenbach   +4 more
core   +1 more source

Comparative Analysis of the Effectiveness of Generic and Brand-Name Cefepime: A Multicenter Retrospective Cohort Study

open access: yesLife
The clinical effectiveness of generic and brand-name cefepime in real-world settings remains unclear. Given the potential implications for healthcare costs and patient outcomes, this study aims to compare the efficacy and safety of these two formulations.
Chih-Huang Li   +3 more
doaj   +1 more source

Clinical Model‐Informed Precision Dosing Consult Service for Accelerating Personalized Medication in Pediatric Patients

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Traditional dosing strategies often rely on a “one‐size‐fits‐all” paradigm, assuming an “average” patient with typical demographic and pharmacological characteristics. In reality, this often overlooks existing between‐patient variability and can lead to suboptimal drug exposure or toxicity. This issue is especially pronounced in pediatric patients, who
Zachary L. Taylor   +12 more
wiley   +1 more source

Synergistic Effects of Gentamicin, Cefepime, and Ciprofloxacin on Biofilm of Pseudomonas aeruginosa

open access: yes, 2023
Muhammad Usman,1 Arooj Marcus,1 Aimen Fatima,1 Bushra Aslam,1 Maryam Zaid,1 Muska Khattak,1 Sidra Bashir,1 Safia Masood,1 Zara Rafaque,2 Javid Iqbal Dasti1 1Lab of Microbial Genomics and Epidemiology, Department of Microbiology, Quaid-I-Azam University ...
Bashir S   +9 more
core  

The Effect of Cefepime/Fluorothiazinone Compared with Cefepime/Placebo on Clinical Cure and Microbiological Eradication in Patients with Complicated Urinary Tract Infections: A Prospective Randomized Clinical Trial

open access: yesАнтибиотики и Химиотерапия
The multicenter prospective randomized trial of clinical and microbiological efficacy of cefepime in combination with fluorothiazinone or placebo was conducted to expand the possibilities of empirical therapy for patients with complicated urinary tract ...
V. B. Beloborodov   +12 more
doaj   +1 more source

Incidence and impact of respiratory tract infections on outcomes in patients with status epilepticus: A 20‐year longitudinal observation

open access: yesEpilepsia, EarlyView.
Abstract Objective This study was undertaken to identify the incidence of respiratory tract infections (RTIs) in a large cohort of adult patients with status epilepticus (SE) and to characterize their associations with clinical features and outcome determinants.
Sebastian Berger   +8 more
wiley   +1 more source

Outcomes Associated with Empiric Cefepime for Bloodstream Infections Caused by Ceftriaxone-Resistant, Cefepime-Susceptible Escherichia coli and Klebsiella pneumoniae

open access: yes, 2023
BACKGROUND: Cefepime is a first-line agent for empiric sepsis therapy; however, cefepime use may be associated with increased mortality for extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-E) in a minimum inhibitory concentration (MIC ...
Frescas, Brian E   +4 more
core   +1 more source

Resistance of Gram-Negative Bacteria to Cefepime-Enmetazobactam: A Systematic Review

open access: yesPathogens
Cefepime-enmetazobactam is a novel β-lactam/β-lactamase inhibitor combination showing good activity against multidrug-resistant (MDR) Gram-negative bacteria producing a variety of β-lactamases.
Matthew E. Falagas   +4 more
doaj   +1 more source

Assessing the association between cefepime percentage free trough level and neurotoxicity

open access: yesAntimicrobial Stewardship & Healthcare Epidemiology, 2022
Background: Cefepime has a known association with neurotoxicity due to its ability to cross the blood–brain barrier. The symptoms of neurotoxicity are highly variable.
Aleena Zia   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy